Ap38
FORM 38.5(b) (EPT/NON-RI)
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE
UNDER RULE 38.5(b) AND RULE 38.6 OF THE IRISH TAKEOVER
PANEL ACT, 1997, TAKEOVER RULES, 2022 BY A CONNECTED
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED
INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
(a) Name of exempt principal trader: |
Citigroup Global Markets Europe AG |
(b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree |
Sanofi |
(c) Name of the party to the offer with which exempt principal trader is connected: (Note 1) |
Amgen Inc. |
(d) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure |
01 December 2022 |
(e) In addition to the company in 1(b) above, is the exempt principal trader also making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" |
YES
|
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2 for each additional class of relevant security.
Ap39
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) (Note 2)
Class of relevant security: |
Ordinary Shares |
|||
|
Interests |
Short positions |
||
Number |
% |
Number |
% |
|
(1) Relevant securities owned and/or controlled: |
10,908 |
0.0000 |
0 |
0 |
(2) Cash-settled derivatives: |
N/A |
|
N/A |
|
(3) Stock-settled derivatives (including options) and agreements to purchase/ sell: |
0 |
|
402,140 |
0.03173 |
Total: |
10,908 |
0.0000 |
402,140 |
0.03173 |
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
(Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of |
Purchases/ |
Total |
Highest |
Lowest |
Ordinary Shares |
Sale |
2,000 |
87.2100 |
87.2500 |
Ap40
(b) Cash-settled derivative transactions
Class of |
Product |
Nature of dealing |
Number of |
Price per |
|
|
|
|
|
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of |
Product |
Writing, |
Number of |
Exercise |
Type |
Expiry |
Option |
Warrant |
Call Option |
Purchasing |
500 |
85 |
European |
01-Dec 2022 |
0.3700 |
Warrant |
Call Option |
Purchasing |
1,200 |
75 |
European |
15-Dec-2022 |
1.300 |
Warrant |
Call Option |
Purchasing |
1,300 |
82.5 |
European |
15-Dec-2022 |
0.5700 |
(ii) Exercise
Class of |
Product |
Exercising/ |
Number of |
Exercise |
|
|
|
|
|
(d) Other dealings (including transactions in respect of new securities)
Class of |
Nature of |
Details |
Price per unit |
|
|
|
|
Ap41
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" |
|
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
|
(c) Attachments
Is a Supplemental Form 8 attached? |
YES/NO |
Date of disclosure: |
02 December 2022 |
Contact name: |
Cathal McKenna |
Telephone number: |
028 90 409544 |
Public disclosures under Rule 38 of the Rules must be made to a Regulatory Information Service.
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person making |
Citigroup Global Markets Europe AG |
Name of offeror/offeree in relation |
Sanofi |
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class of |
Product |
Written or |
Number of |
Exercise |
Type |
Expiry |
Warrant |
Call |
Written |
25 |
46.115 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
300 |
58.945 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
1 |
71.684 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
190 |
75.949 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
155 |
72.557 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
7,134 |
50.914 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
470 |
70.334 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
250 |
75.949 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
50 |
67.13 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
100 |
73.536 |
European |
29-Dec-26 |
Warrant |
Call |
Written |
200 |
90 |
European |
15-Dec-22 |
Warrant |
Call |
Written |
200 |
95 |
European |
15-Dec-22 |
Warrant |
Call |
Written |
360 |
110 |
European |
15-Dec-22 |
Warrant |
Call |
Written |
1,000 |
110 |
European |
15-Dec-22 |
Warrant |
Call |
Written |
150 |
114 |
European |
16-Mar-23 |
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest or position can be fully understood: |
|
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)
Class of relevant security in relation to which subscription right exists: |
|
Details, including nature of the rights concerned and relevant percentages: |
|
It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
Ap42
NOTES ON FORM 38.5(b) AND 38.6
1. See the definition of "connected principal trader" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. See Rule 2.5(d) of Part A of the Rules.
6. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
7. If details included in a disclosure under Rule 38 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rules 8 and 38 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.